Park Ha Biological Technology is trading 6% down at $0.44 after shareholders approved a major overhaul of its governance and capital structure at meetings held on July 13, 2026.
- The approved changes include a massive expansion of authorized share capital and a significant increase in Class B voting rights.
- Investors are reacting to the board's new authority to execute large reverse and forward share splits, which has raised concerns regarding potential dilution and shifts in control.